Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact
Pays $54m Upfront To Access Capsids For Brain Diseases
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
